Cargando…
Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV
Antiretroviral pre-exposure prophylaxis (PrEP) is protective against HIV. Low utilization rates amongst HIV vulnerable populations are due in part to the high cost of PrEP. Generic PrEP offers the potential to improve health at significantly reduced costs. In this study, we examine early utilization...
Autores principales: | Ballreich, Jeromie, Levengood, Timothy, Conti, Rena M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341204/ https://www.ncbi.nlm.nih.gov/pubmed/35902088 http://dx.doi.org/10.1017/jme.2022.33 |
Ejemplares similares
-
Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic
por: Killelea, Amy, et al.
Publicado: (2022) -
Do Physicians Have a Duty to Discuss Expanded Access to Investigational Drugs with their Patients? A Normative Analysis
por: Vermeulen, Stefan F., et al.
Publicado: (2023) -
Planning for pre-exposure prophylaxis to prevent HIV transmission: challenges and opportunities
por: Kim, Susan C, et al.
Publicado: (2010) -
Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs
por: Murimi-Worstell, Irene B., et al.
Publicado: (2019) -
Thought Leader Perspectives on Participant Protections in Precision Medicine Research
por: Hammack, Catherine M., et al.
Publicado: (2019)